bioAffinity Technologies Announces Publication of Peer-Reviewed Paper on Proprietary Beads Used in CyPath® Lung for Noninvasive Detection of Early-Stage Lung Cancer
March 28 2023 - 8:00AM
Business Wire
bioAffinity Technologies, Inc. (NASDAQ: BIAF;
BIAFW) today announced the publication of a paper titled
“Porphyrin-modified beads for use as compensation controls in flow
cytometry” in the peer-reviewed Journal of Visualized Experiments
(JoVE). The paper describes the protocol for preparing
porphyrin-labeled compensation beads to optimize the results of
bioAffinity’s CyPath® Lung test to detect early-stage lung
cancer.
bioAffinity Technologies has an international patent pending for
the proprietary compensation beads and their use in flow
cytometry.
“The publication of our peer-reviewed paper in JoVE is a
recognition of our commitment to advancing innovative science in
line with the Company’s mission of improving the survivability of
lung cancer, the world’s deadliest cancer, through expanded
screening and early diagnosis,” said Maria Zannes, President and
CEO of bioAffinity Technologies.
“The beads act as an important control for our CyPath® Lung
assay by allowing the fluorescence of the porphyrin TCPP to be
quantified more accurately,” said William E. Bauta, Ph.D., Senior
Vice President for Therapeutics at bioAffinity Technologies and
inventor of the compensation beads. “The compensation beads we
developed have improved the assay’s precision, lowered costs and
accelerated sample processing.”
As part of CyPath® Lung processing, patient sputum samples are
labeled with the fluorescent porphyrin TCPP
(meso-tetra-(4-carboxyphenyl) porphine). TCPP preferentially binds
to cancer and cancer-related cells in the sputum and fluoresces,
which aids in the detection of early-stage lung cancer.
bioAffinity’s TCPP-modified compensation beads are used with the
flow cytometer to ensure that TCPP fluorescence can be correctly
distinguished from the other fluorescent molecules that are part of
the assay.
CyPath® Lung uses automated flow cytometry and artificial
intelligence to analyze patient samples by identifying parameters
in sputum that are indicative of cancer. In a recent clinical
trial, CyPath® Lung showed 92% sensitivity and 87% specificity in
high-risk patients who had nodules smaller than 20 millimeters or
no nodules in the lung, with an area under the ROC curve of
94%.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for
noninvasive diagnosis of early-stage cancer and diseases of the
lung, and targeted cancer treatment. The Company’s first product,
CyPath® Lung, is a noninvasive test that has shown high sensitivity
and specificity for the detection of early-stage lung cancer.
CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by
Precision Pathology Services. OncoSelect Therapeutics, LLC, a
subsidiary of bioAffinity Technologies, is advancing its
discoveries shown in vitro to kill cancer cells without harm to
normal cells. Research and optimization of the Company’s platform
technologies are conducted in its laboratories at The University of
Texas at San Antonio.
About JoVE
JoVE is a peer-reviewed scientific methods journal that
publishes text and video protocols demonstrated by authors in their
laboratories. JoVE videos facilitate efficient transfer of
techniques within research communities, promote standardization and
collaboration, and accelerate scientific progress. The journal
publishes 1,000+ articles per year from research institutions
around the world. All articles are indexed in PubMed, Web of
Science, Medline and other relevant databases.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements regarding the anticipated use of proceeds from
the Company’s offering of common shares. Forward-looking statements
can be identified by words such as “believes,” “expects,”
“estimates,” “intends,” “may,” “plans,” “will” and similar
expressions, or the negative of these words. Such forward-looking
statements are based on facts and conditions as they exist at the
time such statements are made and predictions as to future facts
and conditions. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230328005298/en/
bioAffinity Technologies Julie Anne Overton Director of
Communications jao@bioaffinitytech.com
LHA Investor Relations Tirth T. Patel tpatel@lhai.com
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Jun 2024 to Jul 2024
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Jul 2023 to Jul 2024